ENTERO THERAPEUTICS INC (ENTO) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ENTO • US33749P5070

2.99 USD
+0.15 (+5.28%)
At close: Nov 28, 2025
3.2 USD
+0.21 (+7.02%)
After Hours: 11/28/2025, 8:25:57 PM
Fundamental Rating

1

Overall ENTO gets a fundamental rating of 1 out of 10. We evaluated ENTO against 524 industry peers in the Biotechnology industry. Both the profitability and financial health of ENTO have multiple concerns. ENTO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ENTO has reported negative net income.
  • ENTO had a negative operating cash flow in the past year.
  • ENTO had negative earnings in each of the past 5 years.
  • ENTO had a negative operating cash flow in each of the past 5 years.
ENTO Yearly Net Income VS EBIT VS OCF VS FCFENTO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • ENTO has a better Return On Assets (-20.48%) than 75.33% of its industry peers.
  • ENTO has a better Return On Equity (-31.45%) than 75.33% of its industry peers.
Industry RankSector Rank
ROA -20.48%
ROE -31.45%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ENTO Yearly ROA, ROE, ROICENTO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

1.3 Margins

  • ENTO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENTO Yearly Profit, Operating, Gross MarginsENTO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

  • The number of shares outstanding for ENTO has been increased compared to 1 year ago.
  • ENTO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ENTO Yearly Shares OutstandingENTO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 500K 1M 1.5M
ENTO Yearly Total Debt VS Total AssetsENTO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -2.59, we must say that ENTO is in the distress zone and has some risk of bankruptcy.
  • ENTO has a Altman-Z score (-2.59) which is in line with its industry peers.
  • A Debt/Equity ratio of 0.01 indicates that ENTO is not too dependend on debt financing.
  • ENTO has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: ENTO outperforms 43.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -2.59
ROIC/WACCN/A
WACCN/A
ENTO Yearly LT Debt VS Equity VS FCFENTO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 2.81 indicates that ENTO has no problem at all paying its short term obligations.
  • With a Current ratio value of 2.81, ENTO is not doing good in the industry: 67.66% of the companies in the same industry are doing better.
  • A Quick Ratio of 2.81 indicates that ENTO has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.81, ENTO is doing worse than 65.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.81
Quick Ratio 2.81
ENTO Yearly Current Assets VS Current LiabilitesENTO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

  • ENTO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.71%, which is quite impressive.
EPS 1Y (TTM)76.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 31.66% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-34.51%
EPS Next 2Y-24.09%
EPS Next 3Y-13.45%
EPS Next 5Y31.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENTO Yearly Revenue VS EstimatesENTO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 100M 200M 300M
ENTO Yearly EPS VS EstimatesENTO Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -100K -200K -300K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ENTO. In the last year negative earnings were reported.
  • Also next year ENTO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENTO Price Earnings VS Forward Price EarningsENTO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENTO Per share dataENTO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 15

4.3 Compensation for Growth

  • ENTO's earnings are expected to decrease with -13.45% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.09%
EPS Next 3Y-13.45%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for ENTO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENTERO THERAPEUTICS INC

NASDAQ:ENTO (11/28/2025, 8:25:57 PM)

After market: 3.2 +0.21 (+7.02%)

2.99

+0.15 (+5.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11
Earnings (Next)03-30
Inst Owners4.54%
Inst Owner Change18.37%
Ins Owners2.89%
Ins Owner Change0%
Market Cap10.05M
Revenue(TTM)N/A
Net Income(TTM)-17.42M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.18
P/tB 0.19
EV/EBITDA N/A
EPS(TTM)-11.09
EYN/A
EPS(NY)-1.77
Fwd EYN/A
FCF(TTM)-0.86
FCFYN/A
OCF(TTM)-0.86
OCFYN/A
SpS0
BVpS16.48
TBVpS15.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.48%
ROE -31.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.81
Quick Ratio 2.81
Altman-Z -2.59
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.12%
EPS Next Y-34.51%
EPS Next 2Y-24.09%
EPS Next 3Y-13.45%
EPS Next 5Y31.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y77.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.53%
OCF growth 3YN/A
OCF growth 5YN/A

ENTERO THERAPEUTICS INC / ENTO FAQ

What is the fundamental rating for ENTO stock?

ChartMill assigns a fundamental rating of 1 / 10 to ENTO.


What is the valuation status of ENTERO THERAPEUTICS INC (ENTO) stock?

ChartMill assigns a valuation rating of 0 / 10 to ENTERO THERAPEUTICS INC (ENTO). This can be considered as Overvalued.


What is the profitability of ENTO stock?

ENTERO THERAPEUTICS INC (ENTO) has a profitability rating of 1 / 10.


What is the financial health of ENTERO THERAPEUTICS INC (ENTO) stock?

The financial health rating of ENTERO THERAPEUTICS INC (ENTO) is 3 / 10.


Can you provide the expected EPS growth for ENTO stock?

The Earnings per Share (EPS) of ENTERO THERAPEUTICS INC (ENTO) is expected to decline by -34.51% in the next year.